GEN Exclusives

More »

GEN News Highlights

More »
Sep 20, 2006

Experimental Agent Against Advanced Metastatic Melanoma Doubles Survival Rate

  • A new molecule designed to battle advanced metastatic melanoma doubles the progression-free survival rate of cancer patients, compared with those receiving a conventional treatment, according to Steven O’Day, M.D., chief of research and director of the melanoma program at The Angeles Clinic and Research Institute.

    Synta Pharmaceuticals developed STA-4783 and funded the study. The drug induces tumor cells to produce a heat shock protein on the cell surface, which flags them for destruction by the patient’s own immune system.

    The double-blind, randomized Phase IIb trial of the anticancer agent STA-4783 involved 81 stage IV melanoma patients at 21 medical centers across the U.S. Results show that patients receiving STA-4783 plus paclitaxel had a median progression-free survival rate of 112 days, compared with 56 days for those receiving paclitaxel alone.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Mindclones and Immortality

Is the idea of making a software copy of a human mind something in the realm of reality or science fiction?